ATE333901T1 - Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin - Google Patents

Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin

Info

Publication number
ATE333901T1
ATE333901T1 AT01990621T AT01990621T ATE333901T1 AT E333901 T1 ATE333901 T1 AT E333901T1 AT 01990621 T AT01990621 T AT 01990621T AT 01990621 T AT01990621 T AT 01990621T AT E333901 T1 ATE333901 T1 AT E333901T1
Authority
AT
Austria
Prior art keywords
biguanine
metformin
arginine
pharmaceutical composition
diabetes
Prior art date
Application number
AT01990621T
Other languages
English (en)
Inventor
Jean-Robert Rapin
Dominique Halbitte
Original Assignee
Dospharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dospharma filed Critical Dospharma
Application granted granted Critical
Publication of ATE333901T1 publication Critical patent/ATE333901T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01990621T 2000-12-29 2001-12-31 Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin ATE333901T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0017332A FR2818906B1 (fr) 2000-12-29 2000-12-29 Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine

Publications (1)

Publication Number Publication Date
ATE333901T1 true ATE333901T1 (de) 2006-08-15

Family

ID=8858430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01990621T ATE333901T1 (de) 2000-12-29 2001-12-31 Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin

Country Status (15)

Country Link
US (2) US7265156B2 (de)
EP (1) EP1349578B1 (de)
JP (1) JP4477301B2 (de)
AT (1) ATE333901T1 (de)
CA (1) CA2435484A1 (de)
CY (1) CY1105736T1 (de)
DE (1) DE60121804T2 (de)
DK (1) DK1349578T3 (de)
ES (1) ES2271103T3 (de)
FR (1) FR2818906B1 (de)
NZ (1) NZ527206A (de)
PT (1) PT1349578E (de)
RU (1) RU2003123491A (de)
WO (1) WO2002053090A2 (de)
ZA (1) ZA200207761B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102596191B (zh) 2009-10-02 2016-12-21 勃林格殷格翰国际有限公司 包含bi‑1356和二甲双胍的药物组合物
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
CN105277705A (zh) * 2014-07-24 2016-01-27 江苏维赛科技生物发展有限公司 一种检测双胍类药物残留的试剂盒的制备及其检测方法
EP3468562A1 (de) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Kombinationen aus linagliptin und metformin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2037002A1 (en) 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
FR2696740B1 (fr) * 1992-10-13 1994-12-30 Dospharma Sa Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments.
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
CA2320900C (en) * 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
ATE269069T1 (de) * 1998-04-29 2004-07-15 Sumitomo Pharma Orale zubereitung enthaltend einen biguanid und eine organische säure
FR2796551B1 (fr) 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
AU2001213150A1 (en) 2000-08-03 2002-02-18 Olga Evgenievna Kolesova Composition of metformin with succinic acid or salts thereof and method for treating diabetes

Also Published As

Publication number Publication date
PT1349578E (pt) 2006-12-29
US20070265349A1 (en) 2007-11-15
ES2271103T3 (es) 2007-04-16
ZA200207761B (en) 2004-05-28
FR2818906B1 (fr) 2004-04-02
RU2003123491A (ru) 2005-01-10
EP1349578A2 (de) 2003-10-08
US20040097399A1 (en) 2004-05-20
WO2002053090A2 (fr) 2002-07-11
DE60121804D1 (de) 2006-09-07
DK1349578T3 (da) 2006-11-27
CY1105736T1 (el) 2010-12-22
CA2435484A1 (fr) 2002-07-11
US7265156B2 (en) 2007-09-04
DE60121804T2 (de) 2007-08-23
WO2002053090A3 (fr) 2003-02-20
JP2004517105A (ja) 2004-06-10
JP4477301B2 (ja) 2010-06-09
FR2818906A1 (fr) 2002-07-05
EP1349578B1 (de) 2006-07-26
NZ527206A (en) 2006-12-22

Similar Documents

Publication Publication Date Title
SE0002102D0 (sv) Chemical compound
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
ATE333901T1 (de) Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin
CY1111543T1 (el) Νεες ενωσεις
SE9904505D0 (sv) Novel compounds
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
RS93604A (en) Substituted phenylacetamides and their use as glucokinase activators
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
EA200400432A1 (ru) Производные мочевины
EA200300323A1 (ru) ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ)
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
SE0100901D0 (sv) New composition
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
SE0102438D0 (sv) New compounds
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
DE50202504D1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
GB0212410D0 (en) Organic compounds
SE0101978D0 (sv) New compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1349578

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee